Please assess the completion status of the following clinical trial:

Trial Title: Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women, between the ages of 18 to 65 years~* Diagnosis of migraine, with or without aura~* Experiences between 1 and 8 migraine attacks per month for the past 12 months~Exclusion Criteria:~* Inability to distinguish other headaches from migraine~* Experiences headache of any kind at a frequency greater than or equal to 15 days per month~* History of resistance to sumatriptan, or non-response to 2 or more other triptans, defined as subjects who have not responded to an adequate dose and duration of treatment~* Current use of medication for migraine prophylaxis that has not been stable (no dose adjustment) for 30 days prior to screening~* Chronic opioid therapy (\>3 consecutive days in the 30 days prior to screening)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sumatriptan (Type: ACTIVE_COMPARATOR): None
- Matching placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).